Matrix metalloproteinases, synaptic injury, and multiple sclerosis

Frontiers in Psychiatry

Volumn 1, Issue OCT, 2010, Pages

  Szklarczyk, Arek ^a   Conant, Katherine ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adhesion molecule; Cadherin; Icam; Matrix metalloproteinase; Mmp; Multiple sclerosis; Synapse

Indexed keywords

EID: 80052381575     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2010.00130     Document Type: Review

References (104)

1. Agrawal, S. M., Lau, L., and Yong, V. W. (2008). MMPs in the central nervous system: where the good guys go bad. Semin. Cell Dev. Biol. 19, 42-51.
2. Althoff, G. E., Wolfer, D. P., Timmesfeld, N., Kanzler, B., Schrewe, H., and Pagenstecher, A. (2010). Long-term expression of tissue-inhibitor of matrix metalloproteinase-1 in the murine central nervous system does not alter the morphological and behavioral phenotype but alleviates the course of experimental allergic encephalomyelitis. Am. J. Pathol. 177, 840-853.
3. Anthony, D. C., Miller, K. M., Fearn, S., Townsend, M. J., Opdenakker, G., Wells, G. M., Clements, J. M., Chandler, S., Gearing, A. J., and Perry, V. H. (1998). Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. J. Neuroimmunol. 87, 62-72.
4. Audoin, B., Au Duong, M. V., Malikova, I., Confort-Gouny, S., Ibarrola, D., Cozzone, P. J., Pelletier, J., and Ranjeva, J. P. (2006). Functional magnetic resonance imaging and cognition at the very early stage of MS. J. Neurol. Sci. 245, 87-91.
5. Benesova, Y., Vasku, A., Novotna, H., Litzman, J., Stourac, P., Beranek, M., Kadanka, Z., and Bednarik, J. (2009). Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult. Scler. 15, 316-322.
6. Benson, D. L., Schnapp, L. M., Shapiro, L., and Huntley, G. W. (2000). Making memories stick: cell-adhesion molecules in synaptic plasticity. Trends Cell Biol. 10, 473-482.
7. Bernal, F., Elias, B., Hartung, H. P., and Kieseier, B. C. (2009). Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. Mult. Scler. 15, 721-727.
8. Biederer, T., Sara, Y., Mozhayeva, M., Atasoy, D., Liu, X., Kavalali, E. T., and Sudhof, T. C. (2002). SynCAM, a synaptic adhesion molecule that drives synapse assembly. Science 297, 1525-1531.
9. Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifi, S., and Kuliopulos, A. (2005). PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120, 303-313.
10. Bozdagi, O., Shan, W., Tanaka, H., Benson, D. L., and Huntley, G. W. (2000). Increasing numbers of synaptic puncta during late-phase LTP: N-cadherin is synthesized, recruited to synaptic sites, and required for potentiation. Neuron 28, 245-259.
11. Brown, T. E., Forquer, M. R., Cocking, D. L., Jansen, H. T., Harding, J. W., and Sorg, B. A. (2007). Role of matrix metalloproteinases in the acquisition and reconsolidation of cocaine-induced conditioned place preference. Learn. Mem. 14, 214-223.
12. Benson, D. L., Schnapp, L. M., Shapiro, L., and Huntley, G. W. (2000). Making memories stick: cell-adhesion molecules in synaptic plasticity. Trends Cell Biol. 10, 473-482.
13. Bernal, F., Elias, B., Hartung, H. P., and Kieseier, B. C. (2009). Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. Mult. Scler. 15, 721-727.
14. Biederer, T., Sara, Y., Mozhayeva, M., Atasoy, D., Liu, X., Kavalali, E. T., and Sudhof, T. C. (2002). SynCAM, a synaptic adhesion molecule that drives synapse assembly. Science 297, 1525-1531.
15. Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifi, S., and Kuliopulos, A. (2005). PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120, 303-313.
16. Bozdagi, O., Shan, W., Tanaka, H., Benson, D. L., and Huntley, G. W. (2000). Increasing numbers of synaptic puncta during late-phase LTP: N-cadherin is synthesized, recruited to synaptic sites, and required for potentiation. Neuron 28, 245-259.
17. Brown, T. E., Forquer, M. R., Cocking, D. L., Jansen, H. T., Harding, J. W., and Sorg, B. A. (2007). Role of matrix metalloproteinases in the acquisition and reconsolidation of cocaine-induced conditioned place preference. Learn. Mem. 14, 214-223.
18. L., Furlan, R., and Martino, G. (2009). Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J. Neurosci. 29, 3442-3452.
19. Cho, R. W., Park, J. M., Wolff, S. B., Xu, D., Hopf, C., Kim, J. A., Reddy, R. C., Petralia, R. S., Perin, M. S., Linden, D. J., and Worley, P. F. (2008). mGluR1/5-dependent long-term depression requires the regulated ectodomain cleavage of neuronal pentraxin NPR by TACE. Neuron 57, 858-871.
20. Comabella, M., Rio, J., Espejo, C., Ruiz de Villa, M., Al-Zayat, H., Nos, C., Deisenhammer, F., Baranzini, S. E., Nonell, L., Lopez, C., Julia, E., Oksenberg, J. R., and Montalban, X. (2009). Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin. Immunol. 130, 145-150.
21. Conant, K., McArthur, J. C., Griffin, D. E., Sjulson, L., Wahl, L. M., and Irani, D. N. (1999). Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Ann. Neurol. 46, 391-398.
22. Conant, K., Wang, Y., Szklarczyk, A., Dudak, A., Mattson, M. P., and Lim, S. T. (2010). Matrix metalloproteinasedependent shedding of intercellular adhesion molecule-5 occurs withlong-term potentiation. Neuroscience 166, 508-521.
23. Cossins, J. A., Clements, J. M., Ford, J., Miller, K. M., Pigott, R., Vos, W., Van der Valk, P., and De Groot, C. J. (1997). Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol. 94, 590-598.
24. Crocker, S. J., Whitmire, J. K., Frausto, R. F., Chertboonmuang, P., Soloway, P. D., Whitton, J. L., and Campbell, I. L. (2006). Persistent macrophage/ microglial activation and myelin disruption after experimental autoimmune encephalomyelitis in tissue inhibitor of metalloproteinase-1-deficient mice. Am. J. Pathol. 169, 2104-2116.
25. D'Andrea, M. R., Derian, C. K., Leturcq, D., Baker, S. M., Brunmark, A., Ling, P., Darrow, A. L., Santulli, R. J., Brass, L. F., and Andrade-Gordon, P. (1998). Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. J. Histochem. Cytochem. 46, 157-164.
26. Diaz-Sanchez, M., Williams, K., DeLuca, G. C., and Esiri, M. M. (2006). Protein co-expression with axonal injury in multiple sclerosis plaques. Acta Neuropathol. 111, 289-299.
27. Ding, J. Y., Kreipke, C. W., Schafer, P., Schafer, S., Speirs, S. L., and Rafols, J. A. (2009). Synapse loss regulated by matrix metalloproteinases in traumatic brain injury is associated with hypoxia inducible factor-1-alpha expression. Brain Res. 1268, 125-134.
28. Fernandes, K. S., Brum, D. G., Sandrim, V. C., Guerreiro, C. T., Barreira, A. A., and Tanus-Santos, J. E. (2009). Matrix metalloproteinase-9 genotypes and haplotypes are associated with multiple sclerosis and with the degree of disability of the disease. J. Neuroimmunol. 214, 128-131.
29. Galboiz, Y., Shapiro, S., Lahat, N., Rawashdeh, H., and Miller, A. (2001). Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferonbeta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann. Neurol. 50, 443-451.
30. Giuliani, F., Fu, S. A., Metz, L. M., and Yong, V. W. (2005a). Effective combination of minocycline and interferonbeta in a model of multiple sclerosis. J. Neuroimmunol. 165, 83-91.
31. Giuliani, F., Metz, L. M., Wilson, T., Fan, Y., Bar-Or, A., and Yong, V. W. (2005b). Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J. Neuroimmunol. 158, 213-221.
32. Gold, S. M., Sasidhar, M. V., Morales, L. B., Du, S., Sicotte, N. L., Tiwari-Woodruff, S. K., and Voskuhl, R. R. (2009). Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha). Lab. Invest. 89, 1076-1083.
33. Goncalves DaSilva, A., and Yong, V. W. (2009). Matrix metalloproteinase-12 deficiency worsens relapsing-remitting experimental autoimmune encephalomyelitis in association with cytokine and chemokine dysregulation. Am. J. Pathol. 174, 898-909.
34. Gonzalez-Rosa, J. J., Vazquez-Marrufo, M., Vaquero, E., Duque, P., Borges, M., Gamero, M. A., Gomez, C. M., and Izquierdo, G. (2006). Differential cognitive impairment for diverse forms of multiple sclerosis. BMC Neurosci. 7, 39.
35. Gu, Z., Kaul, M., Yan, B., Kridel, S. J., Cui, J., Strongin, A., Smith, J. W., Liddington, R. C., and Lipton, S. A. (2002). S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297, 1186-1190.
36. Hinkle, C. L., Diestel, S., Lieberman, J., and Maness, P. F. (2006). Metalloprotease-induced ectodomain shedding of neural cell adhesion molecule (NCAM). J. Neurobiol. 66, 1378-1395.
37. Hsu, J. Y., McKeon, R., Goussev, S., Werb, Z., Lee, J. U., Trivedi, A., and Noble-Haeusslein, L. J. (2006). Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury. J. Neurosci. 26, 9841-9850.
38. Iimuro, Y., Nishio, T., Morimoto, T., Nitta, T., Stefanovic, B., Choi, S. K., Brenner, D. A., and Yamaoka, Y. (2003). Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 124, 445-458.
39. Jourquin, J., Tremblay, E., Decanis, N., Charton, G., Hanessian, S., Chollet, A. M., Le Diguardher, T., Khrestchatisky, M., and Rivera, S. (2003). Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. Eur. J. Neurosci. 18, 1507-1517.
40. Jovanova-Nesic, K., and Shoenfeld, Y. (2006). MMP-2, VCAM-1 and NCAM-1 expression in the brain of rats with experimental autoimmune encephalomyelitis as a trigger mechanism for synaptic plasticity and pathology. J. Neuroimmunol. 181, 112-121.
41. Kieseier, B. C., Kiefer, R., Clements, J. M., Miller, K., Wells, G. M., Schweitzer, T., Gearing, A. J., and Hartung, H. P. (1998). Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 121(Pt 1), 159-166.
42. Kieseier, B. C., Seifert, T., Giovannoni, G., and Hartung, H. P. (1999). Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology 53, 20-25.
43. Kohutek, Z. A., diPierro, C. G., Redpath, G. T., and Hussaini, I. M. (2009). ADAM-10-mediated N-cadherin cleavage is protein kinase C-alpha dependent and promotes glioblastoma cell migration. J. Neurosci. 29, 4605-4615.
44. Koshikawa, N., Minegishi, T., Sharabi, A., Quaranta, V., and Seiki, M. (2005). Membrane-type matrix metalloproteinase-1 (MT1-MMP) is a processing enzyme for human laminin gamma 2 chain. J. Biol. Chem. 280, 88-93.
45. Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444-1452.
46. Larsen, P. H., DaSilva, A. G., Conant, K., and Yong, V. W. (2006). Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. J. Neurosci. 26, 2207-2214.
47. Lee, H. M., Kim, H. J., Won, K. J., Choi, W. S., Lee, K. Y., Bae, Y. M., Park, P. J., Park, T. K., Lee, Y. L., Lee, C. K., and Kim, B. (2008). Contribution of soluble intercellular adhesion molecule-1 to the migration of vascular smooth muscle cells. Eur. J. Pharmacol. 579, 260-268.
48. Lee, R., Kermani, P., Teng, K. K., and Hempstead, B. L. (2001). Regulation of cell survival by secreted proneurotrophins. Science 294, 1945-1948.
49. Leppert, D., Waubant, E., Burk, M. R., Oksenberg, J. R., and Hauser, S. L. (1996). Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40, 846-852.
50. Lindberg, R. L., De Groot, C. J., Montagne, L., Freitag, P., van der Valk, P., Kappos, L., and Leppert, D. (2001). The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 124, 1743-1753.
51. Lu, X., Rong, Y., and Baudry, M. (2000). Calpain-mediated degradation ofPSD-95 in developing and adult rat brain. Neurosci. Lett. 286, 149-153.
52. Lyons, P. D., and Benveniste, E. N. (1998). Cleavage of membrane-associated ICAM-1 from astrocytes: involvement of a metalloprotease. Glia 22, 103-112.
53. Maeda, A., and Sobel, R. A. (1996). Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55, 300-309.
54. Maiya, R., Zhou, Y., Norris, E. H., Kreek, M. J., and Strickland, S. (2009). Tissue plasminogen activator modulates the cellular and behavioral response to cocaine. Proc. Natl. Acad. Sci. U.S.A. 106, 1983-1988.
55. Meighan, P. C., Meighan, S. E., Davis, C. J., Wright, J. W., and Harding, J. W. (2007). Effects of matrix metalloproteinase inhibition on short- and long-term plasticity of schaffer collateral/ CA1 synapses. J. Neurochem. 102, 2085-2096.
56. Meighan, S. E., Meighan, P. C., Choudhury, P., Davis, C. J., Olson, M. L., Zornes, P. A., Wright, J. W., and Harding, J. W. (2006). Effects of extracellular matrixdegrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity. J. Neurochem. 96, 1227-1241.
57. Metz, L. M., Zhang, Y., Yeung, M., Patry, D. G., Bell, R. B., Stoian, C. A., Yong, V. W., Patten, S. B., Duquette, P., Antel, J. P., and Mitchell, J. R. (2004). Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol. 55, 756.
58. Michaluk, P., Kolodziej, L., Mioduszewska, B., Wilczynski, G. M., Dzwonek, J., Jaworski, J., Gorecki, D. C., Ottersen, O. P., and Kaczmarek, L. (2007). Beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity. J. Biol. Chem. 282, 16036-16041.
59. Milward, E., Kim, K. J., Szklarczyk, A., Nguyen, T., Melli, G., Nayak, M., Deshpande, D., Fitzsimmons, C., Hoke, A., Kerr, D., Griffin, J. W., Calabresi, P. A., and Conant, K. (2008). Cleavage of myelin associated glycoprotein by matrix metalloproteinases. J. Neuroimmunol. 193, 140-148.
60. Mirowska-Guzel, D., Gromadzka, G., Czlonkowski, A., and Czlonkowska, A. (2009). Association of MMP1, MMP3, MMP9, and MMP12 polymorphisms with risk and clinical course of multiple sclerosis in a Polish population. J. Neuroimmunol. 214, 113-117.
61. Mizoguchi, H., Yamada, K., Mouri, A., Niwa, M., Mizuno, T., Noda, Y., Nitta, A., Itohara, S., Banno, Y., and Nabeshima, T. (2007). Role of matrix metalloproteinase and tissue inhibitor of MMP in methamphetamineinduced behavioral sensitization and reward: implications for dopamine receptor down-regulation and dopamine release. J. Neurochem. 102, 1548-1560.
62. Monea, S., Jordan, B. A., Srivastava, S., DeSouza, S., and Ziff, E. B. (2006). Membrane localization of membrane type 5 matrix metalloproteinase by AMPA receptor binding protein and cleavage of cadherins. J. Neurosci. 26, 2300-2312.
63. Muller, D., Mendez, P., De Roo, M., Klauser, P., Steen, S., and Poglia, L. (2010). Role of NCAM in spine dynamics and synaptogenesis. Adv. Exp. Med. Biol. 663, 245-256.
64. Nagy, V., Bozdagi, O., Matynia, A., Balcerzyk, M., Okulski, P., Dzwonek, J., Costa, R. M., Silva, A. J., Kaczmarek, L., and Huntley, G. W. (2006). Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J. Neurosci. 26, 1923-1934.
65. Noble, L. J., Donovan, F., Igarashi, T., Goussev, S., and Werb, Z. (2002). Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J. Neurosci. 22, 7526-7535.
66. Pauly, T., Ratliff, M., Pietrowski, E., Neugebauer, R., Schlicksupp, A., Kirsch, J., and Kuhse, J. (2008). Activity-dependent shedding of the NMDA receptor glycine binding site by matrix metalloproteinase 3: a PUTATIVE mechanism of postsynaptic plasticity. PLoS ONE 3, e2681. doi:10.1371/journal. pone.0002681.
67. Popovic, N., Schubart, A., Goetz, B. D., Zhang, S. C., Linington, C., and Duncan, I. D. (2002). Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann. Neurol. 51, 215-223.
68. Ranjeva, J. P., Audoin, B., Au Duong, M. V., Confort-Gouny, S., Malikova, I., Viout, P., Soulier, E., Pelletier, J., and Cozzone, P. J. (2006). Structural and functional surrogates of cognitive impairment at the very early stage of multiple sclerosis. J. Neurol. Sci. 245, 161-167.
69. Rossi, S., Furlan, R., De Chiara, V., Musella, A., Lo Giudice, T., Mataluni, G., Cavasinni, F., Cantarella, C., Bernardi, G., Muzio, L., Martorana, A., Martino, G., and Centonze, D. (2009). Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis. Neurobiol. Dis. 36, 51-59.
70. Sakurai, E., Hashikawa, T., Yoshihara, Y., Kaneko, S., Satoh, M., and Mori, K. (1998). Involvement of dendritic adhesion molecule telencephalin in hippocampal long-term potentiation. Neuroreport 9, 881-886.
71. Sbai, O., Ferhat, L., Bernard, A., Gueye, Y., Ould-Yahoui, A., Thiolloy, S., Charrat, E., Charton, G., Tremblay, E., Risso, J. J., Chauvin, J. P., Arsanto, J. P., Rivera, S., and Khrestchatisky, M. (2008). Vesicular trafficking and secretion of matrix metalloproteinases-2, -9 and tissue inhibitor of metalloproteinases-1 in neuronal cells. Mol. Cell. Neurosci. 39, 549-568.
72. Schulz, D., Kopp, B., Kunkel, A., and Faiss, J. H. (2006). Cognition in the early stage of multiple sclerosis. J. Neurol. 253, 1002-1010.
73. Shiryaev, S. A., Savinov, A. Y., Cieplak, P., Ratnikov, B. I., Motamedchaboki, K., Smith, J. W., and Strongin, A. Y. (2009). Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS ONE 4, e4952. doi:10.1371/journal. pone.0004952.
74. Sicotte, N. L., Liva, S. M., Klutch, R., Pfeiffer, P., Bouvier, S., Odesa, S., Wu, T. C., and Voskuhl, R. R. (2002). Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann. Neurol. 52, 421-428.
75. Sorensen, T. L., and Ransohoff, R. M. (1998). Etiology and pathogenesis of multiple sclerosis. Semin. Neurol. 18, 287-294.
76. Spiegel, I., Adamsky, K., Eshed, Y., Milo, R., Sabanay, H., Sarig-Nadir, O., Horresh, I., Scherer, S. S., Rasband, M. N., and Peles, E. (2007). A central role for Necl4 (SynCAM4) in Schwann cellaxon interaction and myelination. Nat. Neurosci. 10, 861-869.
77. Stan, A., Pielarski, K. N., Brigadski, T., Wittenmayer, N., Fedorchenko, O., Gohla, A., Lessmann, V., Dresbach, T., and Gottmann, K. (2010). Essential cooperation of N-cadherin and neuroligin-1 in the transsynaptic control of vesicle accumulation. Proc. Natl. Acad. Sci. U.S.A. 107, 11116-11121.
78. Stuve, O., Dooley, N. P., Uhm, J. H., Antel, J. P., Francis, G. S., Williams, G., and Yong, V. W. (1996). Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40, 853-863.
79. Szklarczyk, A., Conant, K., Owens, D. F., Ravin, R., McKay, R. D., and Gerfen,C. (2007a). Matrix metalloproteinase-7 modulates synaptic vesicle recycling and induces atrophy of neuronal synapses. Neuroscience 149, 87-98.
80. Szklarczyk, A., Oyler, G., McKay, R., Gerfen, C., and Conant, K. (2007b). Cleavage of neuronal synaptosomalassociated protein of 25 kDa by exogenous matrix metalloproteinase-7. J. Neurochem. 102, 1256-1263.
81. Szklarczyk, A., Ewaleifoh, O., Beique, J. C., Wang, Y., Knorr, D., Haughey, N., Malpica, T., Mattson, M. P., Huganir, R., and Conant, K. (2008). MMP-7 cleaves the NR1 NMDA receptor subunit and modifies NMDA receptor function. FASEB J. 22, 3757-3767.
82. Szklarczyk, A., Lapinska, J., Rylski, M., McKay, R. D., and Kaczmarek, L. (2002). Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J. Neurosci. 22, 920-930.
83. Takeuchi, A., and O'Leary, D. D. (2006). Radial migration of superficial layer cortical neurons controlled by novel Ig cell adhesion molecule MDGA1. J. Neurosci. 26, 4460-4464.
84. Tang, L., Hung, C. P., and Schuman, E. M. (1998). A role for the cadherin family of cell adhesion molecules in hippocampal long-term potentiation. Neuron 20, 1165-1175.
85. Thornton, P., Pinteaux, E., Allan, S. M., and Rothwell, N. J. (2008). Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity. Mol. Cell. Neurosci. 37, 135-142.
86. Tian, L., Stefanidakis, M., Ning, L., Van Lint, P., Nyman-Huttunen, H., Libert, C., Itohara, S., Mishina, M., Rauvala, H., and Gahmberg, C. G. (2007). Activation of NMDA receptors promotes dendritic spine development through MMP-mediated ICAM-5 cleavage. J. Cell Biol. 178, 687-700.
87. Togashi, H., Abe, K., Mizoguchi, A., Takaoka, K., Chisaka, O., and Takeichi, M. (2002). Cadherin regulates dendritic spine morphogenesis. Neuron 35, 77-89.
88. Toth, M., Osenkowski, P., Hesek, D., Brown, S., Meroueh, S., Sakr, W., Mobashery, S., and Fridman, R. (2005). Cleavage at the stem region releases an active ectodomain of the membrane type 1 matrix metalloproteinase. Biochem. J. 387, 497-506.
89. Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mork, S., and Bo, L. (1998). Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285.
90. Trapp, B. D., Wujek, J. R., Criste, G. A., Jalabi, W., Yin, X., Kidd, G. J., Stohlman, S., and Ransohoff, R. (2007). Evidence for synaptic stripping by cortical microglia. Glia 55, 360-368.
91. Trivedi, A., Hsu, J. Y., Lin, Y., Goussev, S., Gan, J., Topp, K. S., and Noble-Haeusslein, L. J. (2005). The effects of acute and extended inhibition of matrix metalloproteinases on demyelination and functional recovery after spinal cord injury. Int. J. Neuroprot. Neuroregener. 2, 30-30.
92. VanSaun, M., and Werle, M. J. (2000). Matrix metalloproteinase-3 removes agrin from synaptic basal lamina. J. Neurobiol. 43, 140-149.
93. Vercellino, M., Plano, F., Votta, B., Mutani, R., Giordana, M. T., and Cavalla, P. (2005). Grey matter pathology in multiple sclerosis. J. Neuropathol. Exp. Neurol. 64, 1101-1107.
94. Vos, C. M., Sjulson, L., Nath, A., McArthur, J. C., Pardo, C. A., Rothstein, J., and Conant, K. (2000). Cytotoxicity by matrix metalloprotease-1 in organotypic spinal cord and dissociated neuronal cultures. Exp. Neurol. 163, 324-330.
95. Vos, C. M., van Haastert, E. S., de Groot, C. J., van der Valk, P., and de Vries, H. E. (2003). Matrix metalloproteinase-12 is expressed in phagocytotic macrophages in active multiple sclerosis lesions. J. Neuroimmunol. 138, 106-114.
96. Wang, H., and Reiser, G. (2003). Thrombin signaling in the brain: the role of protease-activated receptors. Biol. Chem. 384, 193-202.
97. Weaver, A., Goncalves da Silva, A., Nuttall, R. K., Edwards, D. R., Shapiro, S. D., Rivest, S., and Yong, V. W. (2005). An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization. FASEB J. 19, 1668-1670.
98. Wegner, C., Esiri, M. M., Chance, S. A., Palace, J., and Matthews, P. M. (2006). Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 67, 960-967.
99. Weiner, H. L. (2009). The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann. Neurol. 65, 239-248.
100. Williams, H., Johnson, J. L., Jackson, C. L., White, S. J., and George, S. J. (2010). MMP-7 mediates cleavage of N-cadherin and promotes smooth muscle cell apoptosis. Cardiovasc. Res. 87, 137-146.
101. Yong, V. W., Agrawal, S. M., and Stirling, D. P. (2007). Targeting MMPs in acute and chronic neurological conditions. Neurotherapeutics 4, 580-589.
102. Yong, V. W., Krekoski, C. A., Forsyth, P. A., Bell, R., and Edwards, D. R. (1998). Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 21, 75-80.
103. Yuan, W., Matthews, R. T., Sandy, J. D., and Gottschall, P. E. (2002). Association between protease-specific proteolytic cleavage of brevican and synaptic loss in the dentate gyrus of kainate-treated rats. Neuroscience 114, 1091-1101.
104. Zhu, B., Luo, L., Moore, G. R., Paty, D. W., and Cynader, M. S. (2003). Dendritic and synaptic pathology in experimental autoimmune encephalomyelitis. Am. J. Pathol. 162, 1639-1650.